Home/Pipeline/GIP-neutralizing antibody

GIP-neutralizing antibody

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Helicore Biopharma

About Helicore Biopharma

Helicore Biopharma is a private, preclinical-stage biotech developing a novel antibody therapeutic targeting the GIP hormone for the treatment of obesity and related metabolic disorders. Its differentiated strategy involves directly binding and neutralizing the circulating GIP ligand, aiming to block its action in both peripheral tissues and the central nervous system to reduce body weight and improve metabolic health. The company is backed by a seasoned management team and leading life science venture capital firms, including OrbiMed, Versant Ventures, and Longitude Capital. Helicore is positioned in the high-growth obesity therapeutics market but faces significant risks typical of early-stage drug development.

View full company profile

Therapeutic Areas

Obesity Metabolic Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active